Takeda (United States)

Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials

BACKGROUND: Narcolepsy type 1 is characterized by excessive daytime sleepiness, cataplexy, disrupted sleep, sleep paralysis, and hypnagogic or hypnopompic hallucinations. Oveporexton (TAK-861), an oral orexin receptor 2-selective agonist, reduced symptoms of narcolepsy type 1 in...

Predictive Safety in the Era of Artificial Intelligence: Promises, Limits, and the Case for an Enterprise Lifecycle Evidence Ecosystem

Drug safety remains central to patient benefit, as maximizing the value of beneficial therapies requires recognition, appropriate characterization, and effective mitigation of treatment-related adverse drug reactions (ADRs). These challenges, particularly with the advent of artif...

A Generalization of the Ternary Binding Model to Membrane‐Confined Systems With Finite Copy Number

ABSTRACT The standard Douglass ternary binding model (TBM) for three‐body equilibria assumes a well‐mixed, three‐dimensional solution. When applied to bispecific T‐cell engagers (BiTEs), however, the productive trimeric complex forms not in bulk solution but within a nanoscale me...